References
- GibbAYangLPOlodaterol: first global approvalDrugs2013731841184624158691
- BouyssouTCasarosaPNalineEPharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical modelsJ Pharmacol Exp Ther2010334536220371707
- CasarosaPKollakIKiechleTFunctional and biochemical rationales for the 24-hour-long duration of action of olodaterolJ Pharmacol Exp Ther201133760060921357659
- FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
- KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
- HodderRPriceDPatient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhalerInt J Chron Obstruct Pulmon Dis2009438139019888356
- Striverdi Respimat (olodaterol) inhalation spray for oral inhalation [prescribing information]2014 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203108s000lbl.pdfAccessed October 25, 2014
- van NoordJASmeetsJJDrenthBM24-Hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPDPulm Pharmacol Ther20112466667221839850
- US Food Drug AdministrationGuidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function – Study Design, Data Analysis, and Impact on Dosing and LabelingRockville (MD)FDA2003
- US Food Drug AdministrationGuidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function – Study Design, Data Analysis, and Impact on Dosing and LabelingRockville (MD)FDA1998
- BorghardtJMWeberBStaabAKunzCFormellaSKloftCInvestigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approachBr J Clin Pharmacol Epub201598
- Antonelli IncalziRFusoLDe RosaMCo-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary diseaseEur Respir J199710279428009493663
- PughRNMurray-LyonIMDawsonJLPietroniMCWilliamsRTransection of the oesophagus for bleeding oesophageal varicesBr J Surg1973606466494541913
- AdamusWSPharmacodynamic methods for investigating antiasthma drugs in healthy volunteersMethods Find Exp Clin Pharmacol1998201391459604856
- VincentHHBoomsmaFMan in’t VeldAJDerkxFHWentingGJSchalekampMAEffects of selective and nonselective β-agonists on plasma potassium and norepinephrineJ Cardiovasc Pharmacol198461071146199591
- TietzNWPrüdenELSiggaard-AndersenOElectrolytesBurtisCAAshwoodERTietz Textbook of Clinical Chemistry2nd edPhiladelphiaWB Saunders199413541374
- ZhangYZhangLAbrahamSAssessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applicationsClin Pharmacol Ther20098530531119020495
- ElliottMJRonksleyPEClaseCMAhmedSBHemmelgarnBRManagement of patients with acute hyperkalemiaCMAJ20101821631163520855477